NewDEL Biotech

Shenzhen NewDEL Biotech Co., Ltd. is a startup company that focuses on innovative drug development and technical services using DNA Encoded Library (DEL) technology as its core. Relying on its proprietary DEL technology, NewDEL Biotech has established an innovative drug lifecycle system dedicated to the design, research, and industrialization of First-in-Class (FIC) drugs to address unmet clinical needs. The company aims to become a globally leading biopharmaceutical company with distinctive new drug research and development capabilities. Notably, the company owns a unique live-cell screening technology in the DEL field, which can screen challenging targets such as hard-to-purify membrane proteins. This screening method, which closely mimics physiological conditions, significantly improves the success rate of drug screening and has been widely applied in the company's new drug development process, primarily focusing on anti-cancer drug research.